Key Points
- CEO Martine Rothblatt sold 9,500 United Therapeutics shares at an average price of $494.79, generating approximately $4.7 million. Her remaining stake totaled 324,443 shares, worth roughly $160.5 million.
- United Therapeutics reported quarterly earnings of $7.27 per share, beating analyst expectations of $6.86, while revenue of $783.3 million fell short of estimates and declined 1.9% year over year.
- Analysts maintain a generally positive view, with an average rating of “Moderate Buy” and a consensus price target of $646, compared with the stock’s opening price of $493.10.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Friday, September 18th. The shares were sold at an average price of $494.79, for a total value of $4,700,505.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $160,531,151.97. The trade was a 2.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
United Therapeutics Stock Down 0.3%
Shares of UTHR stock opened at $493.10 on Tuesday. United Therapeutics Corporation has a twelve month low of $409.07 and a twelve month high of $609.35. The company has a market cap of $21.15 billion, a P/E ratio of 17.64, a P/E/G ratio of 2.48 and a beta of 0.56. The business has a fifty day simple moving average of $514.63 and a 200 day simple moving average of $540.46.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period last year, the firm posted $6.41 earnings per share. United Therapeutics's revenue was down 1.9% compared to the same quarter last year. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 26.21 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of analysts have weighed in on UTHR shares. Royal Bank Of Canada decreased their target price on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th. JPMorgan Chase & Co. increased their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a research report on Thursday, July 23rd. Bank of America decreased their target price on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research note on Friday, July 10th. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research note on Thursday, August 6th. Finally, Weiss Ratings lowered United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research report on Thursday, August 27th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $646.00.
View Our Latest Report on United Therapeutics
Institutional Trading of United Therapeutics
Hedge funds have recently bought and sold shares of the business. Security National Bank of SO Dak bought a new position in United Therapeutics during the second quarter valued at about $179,000. Talon Private Wealth LLC grew its stake in United Therapeutics by 31.8% in the 2nd quarter. Talon Private Wealth LLC now owns 6,753 shares of the biotechnology company's stock valued at $3,659,000 after buying an additional 1,630 shares in the last quarter. Sequoia Financial Advisors LLC lifted its holdings in United Therapeutics by 4.4% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 2,530 shares of the biotechnology company's stock worth $1,371,000 after purchasing an additional 106 shares in the last quarter. Tidal Investments LLC lifted its holdings in shares of United Therapeutics by 1.6% in the second quarter. Tidal Investments LLC now owns 34,012 shares of the biotechnology company's stock worth $18,429,000 after buying an additional 547 shares in the last quarter. Finally, Archford Capital Strategies LLC bought a new position in United Therapeutics in the 2nd quarter valued at $552,000. 94.08% of the stock is currently owned by institutional investors.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company's products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.
United Therapeutics' PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
